University of Colorado Cancer Center


 

Brain Mets & CNS Coverage of MET Signaling in NSCLC: Alectinib vs. Crizotinib, Unmet Need in ROS1, TKI Resistance

88 views
June 11, 2021
0 Comments
Login to view comments. Click here to Login
Oncology Grand Rounds